[go: up one dir, main page]

PE20191475A1 - (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas - Google Patents

(aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas

Info

Publication number
PE20191475A1
PE20191475A1 PE2019001334A PE2019001334A PE20191475A1 PE 20191475 A1 PE20191475 A1 PE 20191475A1 PE 2019001334 A PE2019001334 A PE 2019001334A PE 2019001334 A PE2019001334 A PE 2019001334A PE 20191475 A1 PE20191475 A1 PE 20191475A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
benzothiophen
sulfonamides
indol
Prior art date
Application number
PE2019001334A
Other languages
English (en)
Inventor
Christa E Mueller
Cecile Pegurier
Michael Louis Robert Deligny
Ali El-Tayeb
Joerg Hockemeyer
Marie Ledecq
Joel Mercier
Laurent Provins
Nader M Boshta
Sanjay Bhattaral
Vigneshwaran Namasivayam
Mario Funke
Lukas Schwach
Sabrina Gollos
LAUFENBERG Daniel VON
Anais Barre
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of PE20191475A1 publication Critical patent/PE20191475A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion se refiere a compuestos de sulfonamida de formula I-2, donde X1 es N o CR7; X2 es NH, S u O; X3 es N o CR12; R2 es H, halogeno o metoxi; R4 es H, metoxi o halogeno; R5 es H, halogeno, CN, alquilo C1-C6, entre otros; R6 es H, OH, CN, nitro, halogeno, entre otros; R7 es H, halogeno, CN, nitro, entre otros; R8 es H, alquilo C1-C6, alcoxi C1-C6, entre otros; R9 es H, halogeno, azido, CN, entre otros; R10 es H, halogeno, alquilo C1-C6, amino, entre otros; R11 es H, CN, azido, entre otros; R12 es H, alquilo C1-C6, halogeno, entre otros. Dichos compuestos son moduladores de los receptores acoplados a la proteina G (GPR), en especifico GPR17 y son utiles para tratar o prevenir una variedad de enfermedades del SNC y otras enfermedades, en particular para prevenir y tratar enfermedades o trastornos mielinizantes
PE2019001334A 2016-12-28 2017-12-27 (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas PE20191475A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16207137 2016-12-28
PCT/EP2017/084602 WO2018122232A1 (en) 2016-12-28 2017-12-27 (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides

Publications (1)

Publication Number Publication Date
PE20191475A1 true PE20191475A1 (es) 2019-10-16

Family

ID=57614285

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001334A PE20191475A1 (es) 2016-12-28 2017-12-27 (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas

Country Status (26)

Country Link
US (4) US11345662B2 (es)
EP (1) EP3562820A1 (es)
JP (2) JP6946436B2 (es)
KR (1) KR102537100B1 (es)
CN (3) CN116283712B (es)
AR (1) AR110592A1 (es)
AU (2) AU2017387695B2 (es)
CA (1) CA3045244A1 (es)
CL (1) CL2019001660A1 (es)
CO (1) CO2019007829A2 (es)
CR (1) CR20190287A (es)
EA (1) EA201991553A1 (es)
EC (1) ECSP19044183A (es)
IL (2) IL295047B2 (es)
MX (1) MX2019006190A (es)
MY (1) MY199872A (es)
NZ (1) NZ753651A (es)
PE (1) PE20191475A1 (es)
PH (1) PH12019501095A1 (es)
RU (1) RU2767904C2 (es)
TN (1) TN2019000165A1 (es)
TW (1) TWI754702B (es)
UA (1) UA127890C2 (es)
UY (1) UY37554A (es)
WO (1) WO2018122232A1 (es)
ZA (1) ZA201903466B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
MX2020011050A (es) * 2018-04-20 2021-03-09 Virginia Tech Intellectual Properties Inc Imidazopiridinas útiles como desacopladores mitocondriales.
TWI857957B (zh) * 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
TW202024023A (zh) * 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN110128422B (zh) * 2019-01-04 2022-03-18 金凯(辽宁)生命科技股份有限公司 5-甲氧基-7-氮杂吲哚的合成方法
WO2020150439A1 (en) * 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
GB201903671D0 (en) * 2019-03-18 2019-05-01 Univ Edinburgh Small molecule photosensitizers for photodynamic therapy
US12358875B2 (en) * 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
EP4143303A4 (en) * 2020-05-01 2024-09-04 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR PROMOTING MYELINIZATION
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
CN112266328B (zh) * 2020-12-09 2023-11-03 郑州萃智医药科技有限公司 3-氟-4-硝基苯甲醛的合成路线及制备方法
AU2022227183A1 (en) * 2021-02-26 2023-06-22 F. Hoffmann-La Roche Ag Novel pyrimidin-2-yl sulfonamide derivatives
TW202313569A (zh) * 2021-06-04 2023-04-01 比利時商理溫醫療公司 吡咯基磺胺化合物
TW202317087A (zh) 2021-08-10 2023-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關病況之化合物及組合物
CN114276319B (zh) * 2022-01-06 2023-11-03 滁州学院 一种劳拉替尼中间体的合成方法
CN114315741B (zh) * 2022-01-19 2023-09-12 贵州医科大学 一种硫代化合物及其制备方法与应用
JP2025523939A (ja) 2022-07-20 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー 新規のナフチルおよびイソキノリンスルホンアミド誘導体
WO2024017855A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
WO2024017857A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives
JP2025523899A (ja) 2022-07-20 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー 新規ピリミジニルおよびトリアジニルスルホンアミド誘導体
AU2023380534A1 (en) * 2022-11-20 2025-05-22 Myrobalan Therapeutics, Inc. Gpr17 modulators and uses thereof
WO2024115733A1 (en) * 2022-12-02 2024-06-06 Rewind Therapeutics Nv Fused pyrrolyl-sulfonamide compounds
WO2024153233A1 (en) * 2023-01-19 2024-07-25 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as gpr17 antagonists
CN116947879B (zh) * 2023-07-25 2025-10-31 沈阳药科大学 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用
TW202515863A (zh) * 2023-08-15 2025-04-16 美商百健Ｍａ公司 作為ｇｐｒ１７調節劑之吲哚及吡咯并吡啶衍生物
WO2025195241A1 (zh) * 2024-03-19 2025-09-25 迈巴制药(南京)有限公司 Gpr17受体抑制剂及其用途
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2642355A (en) * 2024-07-05 2026-01-07 Pheno Therapeutics Ltd Polymorphs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
EP1159263A1 (en) * 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
NZ528450A (en) * 2001-05-11 2006-02-24 Biovitrum Ab Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders
SE0102048D0 (sv) * 2001-06-11 2001-06-11 Pharmacia Ab New Compounds
WO2005103291A1 (ja) 2004-04-27 2005-11-03 Takeda Pharmaceutical Company Limited Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20042007A1 (it) 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
DE112008002309A5 (de) 2007-06-25 2010-05-27 Acino Ag Elektrophoretisches transdermales Applikationssystem
WO2009080223A1 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US8318725B2 (en) * 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US20110220151A1 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and Apparatus for Washing Downhole Tubulars and Equipment
EP2567698B1 (en) * 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
KR20150008468A (ko) 2012-05-09 2015-01-22 폰다지오네 이탈리아나 스클레로시 멀티플라 - 에프아이에스엠 온러스 Gpr17 수용체 조절제
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
EP2998294A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP2997966A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
WO2016089062A2 (en) * 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
ES2856125T3 (es) * 2016-02-05 2021-09-27 Ea Pharma Co Ltd Derivado de sulfonamida y composición farmacéutica que contiene la misma
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Also Published As

Publication number Publication date
AU2017387695A1 (en) 2019-06-06
IL295047B1 (en) 2024-05-01
ECSP19044183A (es) 2020-01-31
KR20190098243A (ko) 2019-08-21
CN116283712B (zh) 2025-08-19
JP2022003051A (ja) 2022-01-11
TN2019000165A1 (en) 2020-10-05
IL295047A (en) 2022-09-01
NZ753651A (en) 2022-10-28
IL295047B2 (en) 2024-09-01
CA3045244A1 (en) 2018-07-05
AR110592A1 (es) 2019-04-10
CN116036078A (zh) 2023-05-02
BR112019012550A2 (pt) 2019-11-12
WO2018122232A1 (en) 2018-07-05
US12071404B2 (en) 2024-08-27
CN116036078B (zh) 2025-09-02
AU2022235580A1 (en) 2022-10-13
AU2022235580B2 (en) 2024-03-28
US11345662B2 (en) 2022-05-31
KR102537100B1 (ko) 2023-05-25
CL2019001660A1 (es) 2019-10-25
CN110121499B (zh) 2022-12-20
ZA201903466B (en) 2020-11-25
JP7270011B2 (ja) 2023-05-09
IL267438B2 (en) 2023-07-01
UA127890C2 (uk) 2024-02-07
RU2019123031A3 (es) 2021-03-22
RU2767904C2 (ru) 2022-03-22
AU2017387695B2 (en) 2022-06-23
TW201831448A (zh) 2018-09-01
PH12019501095A1 (en) 2019-12-02
EP3562820A1 (en) 2019-11-06
IL267438A (en) 2019-08-29
US20220127227A1 (en) 2022-04-28
IL267438B1 (en) 2023-03-01
EA201991553A1 (ru) 2020-01-09
UY37554A (es) 2018-07-31
CO2019007829A2 (es) 2019-07-31
MY199872A (en) 2023-11-27
US20220048858A1 (en) 2022-02-17
CR20190287A (es) 2019-08-06
TWI754702B (zh) 2022-02-11
CN110121499A (zh) 2019-08-13
JP2020504753A (ja) 2020-02-13
RU2019123031A (ru) 2021-02-01
JP6946436B2 (ja) 2021-10-06
US20230348384A1 (en) 2023-11-02
US20190345104A1 (en) 2019-11-14
MX2019006190A (es) 2019-11-18
US11820746B2 (en) 2023-11-21
CN116283712A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
PE20191475A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
CL2021000384S1 (es) Banda tipo pulsera para un dispositivo.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2020005513A (es) Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
PH12019500231A1 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
UY36838A (es) Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
PE20160996A1 (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
EA201892666A1 (ru) 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
MX2018010191A (es) Inhibidores de glucosidasa.
PH12017501825A1 (en) Bicyclic quinazolinone derivatives
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
CL2021000385S1 (es) Banda tipo pulsera para un dispositivo.
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
BR112022008575A2 (pt) Bloqueadores de canal iônico carregado e métodos para uso
BR112018075597A2 (pt) derivados de carbamato de 2-amino-4-(amino substituído)fenila fluorado
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
EA201892822A1 (ru) Новые антибактериальные соединения
EA201891299A1 (ru) Терапевтические антитела к cd9
AR093581A1 (es) Antibioticos macrociclicos de amplio espectro
CL2020001009A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201991852A1 (ru) Модуляторы печеночного х рецептора (lxr)